Jun 24, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Actinium Pharma (ATNM)

Jun 23, 2025 11:31AM Actinium Pharma (ATNM) Highlights Expanded Data Set for ATNM-400

May 26, 2025 10:20AM INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 25, 2025 09:03AM INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 24, 2025 08:50AM INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 22, 2025 04:00PM ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 21, 2025 09:53AM ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

May 19, 2025 06:40PM SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 17, 2025 08:03AM ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 16, 2025 04:00PM ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 15, 2025 10:20AM DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 12, 2025 05:48PM SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 11, 2025 04:00PM ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 10, 2025 08:04AM INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 5, 2025 04:00PM ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 5, 2025 10:11AM SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 2, 2025 10:19AM Faruqi & Faruqi Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 26, 2025 - ATNM

Apr 29, 2025 04:00PM ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Apr 28, 2025 08:36AM Actinium Pharma (ATNM) Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models

Apr 23, 2025 04:00PM ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Apr 22, 2025 09:30AM INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 17, 2025 04:00PM ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Apr 17, 2025 11:50AM INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 11, 2025 04:00PM ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Apr 10, 2025 04:00PM ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM

Apr 8, 2025 04:03PM Faruqi & Faruqi Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 26, 2025 - ATNM

Apr 7, 2025 06:13PM ROSEN, A LEADING AND RANKED FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM

Apr 6, 2025 04:00PM ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Apr 5, 2025 03:15PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM

Apr 4, 2025 03:10PM ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM

Apr 2, 2025 02:15PM ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM

Apr 1, 2025 08:30PM INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 1, 2025 12:35PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM

Apr 1, 2025 12:29PM Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm

Mar 31, 2025 04:00PM ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Mar 28, 2025 08:00PM ATNM ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc. Investors

Mar 27, 2025 08:45AM Actinium Pharma (ATNM) Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Mar 27, 2025 07:30AM Actinium Pharma (ATNM) Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline

Mar 26, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Actinium Pharma (ATNM)

Mar 24, 2025 04:16PM Actinium Pharma (ATNM) Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

Mar 17, 2025 08:50AM Actinium Pharma (ATNM) Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Mar 11, 2025 08:34AM Actinium Pharma (ATNM) Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly

Nov 19, 2024 06:53AM Stephens Reiterates Overweight Rating on Actinium Pharma (ATNM)

Nov 18, 2024 07:36AM H.C. Wainwright Reiterates Buy Rating on Actinium Pharma (ATNM)

Nov 4, 2024 07:31AM Actinium Pharma (ATNM) Appoints June Almenoff to its Board

Sep 20, 2024 08:02AM Actinium Pharma (ATNM) Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology

Aug 6, 2024 06:38AM Actinium Pharma (ATNM) PT Lowered to $4 at H.C. Wainwright

Aug 5, 2024 02:36PM Actinium Pharma (ATNM) PT Lowered to $9 at Jones Trading

Jul 25, 2024 08:45AM Actinium Pharma (ATNM) Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients

Jun 10, 2024 08:33AM Actinium Pharma (ATNM) Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development